The insulin receptor/insulin-like growth factor receptor family as a therapeutic target in oncology.
about
Theranostic applications of antibodies in oncology.The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potentialInsulin-like growth factor system in cancer: novel targeted therapiesInsulin-mediated signaling promotes proliferation and survival of glioblastoma through Akt activationVEGF/neuropilin-2 regulation of Bmi-1 and consequent repression of IGF-IR define a novel mechanism of aggressive prostate cancerThe IGF Hormonal Network in Endometrial Cancer: Functions, Regulation, and Targeting ApproachesInsulin-like growth factor 2 and its enterocyte receptor are not required for adaptation in response to massive small bowel resection.Engineered ubiquitin ligase PTB-U-box targets insulin/insulin-like growth factor receptor for degradation and coordinately inhibits cancer malignancyTreating breast cancer in the 21st century: emerging biological therapiesEvaluation of a novel hexavalent humanized anti-IGF-1R antibody and its bivalent parental IgG in diverse cancer cell linesA parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours.IGF axis and other factors in HPV-related and HPV-unrelated carcinogenesis (review).Insulin-like growth factor 1 receptor (IGF1R) expression and survival in operable squamous-cell laryngeal cancer.Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells.Evaluation of 99mTc-Z IGF1R:4551-GGGC affibody molecule, a new probe for imaging of insulin-like growth factor type 1 receptor expressionDifferential expression of the insulin-like growth factor receptor among early breast cancer subtypes.Both epidermal growth factor and insulin-like growth factor receptors are dispensable for structural intestinal adaptation.Hsp90 molecular chaperone inhibitors: are we there yet?Metformin Treatment for the Prevention and/or Treatment of Breast/Mammary TumorigenesisProteolytic cleavage, trafficking, and functions of nuclear receptor tyrosine kinases.PAPP-A proteolytic activity enhances IGF bioactivity in ascites from women with ovarian carcinomaCathepsin Inhibition Prevents Autophagic Protein Turnover and Downregulates Insulin Growth Factor-1 Receptor-Mediated Signaling in NeuroblastomaObesity-driven inflammation and cancer risk: role of myeloid derived suppressor cells and alternately activated macrophages.Insulin-like growth factors and insulin-like growth factor-binding proteins and prostate cancer risk: results from the prostate cancer prevention trial.A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial.A novel antitumor activity of deguelin targeting the insulin-like growth factor (IGF) receptor pathway via up-regulation of IGF-binding protein-3 expression in breast cancer.Preclinical and first-in-human phase I studies of KW-2450, an oral tyrosine kinase inhibitor with insulin-like growth factor receptor-1/insulin receptor selectivityA twenty-first century cancer epidemic caused by obesity: the involvement of insulin, diabetes, and insulin-like growth factorsThe CEA-/lo colorectal cancer cell population harbors cancer stem cells and metastatic cells.The decline and fall of the IGF-I receptor.Global analysis of L1-transcriptomes identified IGFBP-2 as a target of ezrin and NF-κB signaling that promotes colon cancer progression.Insulin-like growth factor 2 axis supports the serum-independent growth of malignant rhabdoid tumor and is activated by microenvironment stress.Prevention of tumour cell apoptosis associated with sustained protein kinase B phosphorylation is more sensitive to regulation by insulin signalling than stimulation of proliferation and extracellular signal-regulated kinase.PET imaging of insulin-like growth factor type 1 receptor expression with a 64Cu-labeled Affibody molecule.Association of cancer metabolism-related proteins with oral carcinogenesis - indications for chemoprevention and metabolic sensitizing of oral squamous cell carcinoma?Insulin-like growth factor axis targeting in cancer and tumour angiogenesis - the missing link.Insulin induces drug resistance in melanoma through activation of the PI3K/Akt pathwayInsulin activates the insulin receptor to downregulate the PTEN tumour suppressor.Risk Differences Between Prediabetes And Diabetes According To Breast Cancer Molecular Subtypes.Pappalysin-1 T cell receptor transgenic allo-restricted T cells kill Ewing sarcoma in vitro and in vivo.
P2860
Q27693293-7AEAFD2B-A2A0-4B10-9911-17F1F936DB17Q28075927-55AC0C05-1156-43CE-A9CB-60620D67B5EEQ28081603-E2CC0BC2-77A1-4D50-81C3-F15B9DA2413DQ28396199-07DD66AA-EF13-4325-9B82-463F6C92E9B8Q30595149-5273E5D6-5C52-400D-9B0D-B2C96FCB090CQ33658023-BA7D8937-561D-4BB2-8562-0F9F2B7D058EQ33708431-9D8CBC7F-2470-484A-A24B-7D1404D189D0Q34104101-82FC914C-0DAF-4836-91CE-750ECB50FCC4Q34326536-67C8743D-C9EB-4268-9AD5-5128850BD136Q34406479-A2947DE4-175E-48E8-B237-8F98DA052AECQ34499662-AD40CCEB-4FD4-4771-A656-4E18B3816764Q34556695-396EDADF-C852-40F0-B78F-9AC84D1FD20EQ34568232-B3B89DB0-6F1B-4EF8-AB18-AA755AC76E90Q34569071-68CB162F-9E79-42F5-8C9B-3E933EF0A623Q34996772-F93BCA83-DEDC-4EB3-B906-9D4AF8A46E2AQ35123145-78B5409A-5000-41F6-A8DF-75E67384CA29Q35630090-02DD0C77-3BD5-46DF-B211-224915E185DAQ35655105-EC5FFD86-FEE8-443E-8FDA-61949FF8113BQ36078840-E466E272-DEA9-4B14-9B4A-1F0049CE6FAFQ36113481-44B69FB9-C19A-4778-BA03-A04D932EC34FQ36544836-119668A5-71AF-41F3-BFCC-5B139196A446Q36559668-F3F1E99B-DD80-4114-8FC6-7A31205F1C11Q36562906-8A36BDFA-4C30-4D64-82A6-1788754587A8Q36589091-4604F183-9892-4253-AE9A-99DF048884C2Q36719024-0A84605D-E7C3-48EF-B14D-A3D5BF9693E8Q36800387-EEFFFB07-D8A0-432E-A3EF-276B69871D8BQ36801184-FEF5EE2F-B639-404F-80C3-704CE7557F61Q37105231-054CF6CE-6A0C-4DC7-BD54-24E544528B06Q37697056-681B3A6F-DF8D-4801-93BA-C961CDAA5137Q38038480-42763121-A7A1-4BC5-A026-00F1263ACE57Q38322908-F0AF5782-D3D9-4820-A8F6-6387ADAA38EBQ38682244-47DAFDAE-3AF0-436D-97C4-B1E1B449FBEFQ38711630-5C2636C0-496E-4AE7-9204-6C67BEADBDAFQ38889580-30FF483E-CFBB-4999-84B5-3C9AA713DCECQ38973075-8E2A3435-F245-493F-9B52-AAB857E1877CQ38990201-A31EA6C4-A4DA-4365-8D34-36E528B8F63AQ39018168-FA4140D5-F93D-447F-92DD-893354BCC716Q39101629-F322C4B7-0EDF-403D-B6FB-E0191985FB2AQ40600342-19FE4F16-25DF-4451-9E5A-544831D9BEC7Q42040539-1B17B001-53F6-4964-ABA5-5FA675CFD745
P2860
The insulin receptor/insulin-like growth factor receptor family as a therapeutic target in oncology.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
The insulin receptor/insulin-l ...... herapeutic target in oncology.
@en
The insulin receptor/insulin-l ...... herapeutic target in oncology.
@nl
type
label
The insulin receptor/insulin-l ...... herapeutic target in oncology.
@en
The insulin receptor/insulin-l ...... herapeutic target in oncology.
@nl
prefLabel
The insulin receptor/insulin-l ...... herapeutic target in oncology.
@en
The insulin receptor/insulin-l ...... herapeutic target in oncology.
@nl
P1476
The insulin receptor/insulin-l ...... herapeutic target in oncology.
@en
P2093
Michael Pollak
P356
10.1158/1078-0432.CCR-11-0998
P407
P577
2012-01-01T00:00:00Z